Chinese medical device maker Mindray (NYSE:MR) posted some strong financial figures from its 3rd quarter, but had to curb some of its expectations for the rest of the year as hospital purchases slowed down at home.
Mindray had originally projected an 18% rise in sales, but scaled that figure back to 13%, citing slowing hospital purchasing behavior. Despite the slow-down, the company posted a 15.3% boost in sales and a 14.7% boost in profits for its 3rd quarter of 2013.
"We are revising our financial guidance for 2013, primarily due to the enduring hospital purchase slowdown in China," co-CEO and chief strategic officer Cheng Minghe said in prepared remarks. "In other geographies, we expect some countries to perform well in the emerging markets, but political and currency issues will affect other areas. For the developed markets, we are confident about our expansion in Western Europe and expect the North American business will stabilize."
Mindray posted profits of $165.1 million, or 25¢ per diluted share, on sales of $296.3 million during the 3 months ended September 30. That compares with $144 million in profits, or 30¢ per diluted share, on sales of $257.1 million during the same period last year.
Excluding special charges, per-share earnings came to 47¢, about 5¢ shy of analysts’ consensus estimates.
Mindray also announced a new $200 million share repurchase program, effective immediately and lasting through the next 9 months. The company plans to buy up issued and outstanding ordinary American Depositary Shares on the NYSE Euronext market, according to a press release.